Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chengxin Li

Showing results (161-170 of 162) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 162 results.
The British Journal of Dermatology|February 17, 2024
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Congjun Jiang, Guoqiang Zhang, et al.
The World Allergy Organization Journal|December 22, 2021
Expert consensus on the use of omalizumab in chronic urticaria in ChinaZuotao Zhao, Tao Cai, Hong Chen, et al.
Pageof 17

Showing results (161-170 of 162) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 162 results.
The British Journal of Dermatology|February 17, 2024
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Congjun Jiang, Guoqiang Zhang, et al.
The World Allergy Organization Journal|December 22, 2021
Expert consensus on the use of omalizumab in chronic urticaria in ChinaZuotao Zhao, Tao Cai, Hong Chen, et al.
Pageof 17